Xuemei Peng
Harvard University
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Xuemei Peng.
Pharmacology | 2008
J.D. Reindl; K. Rowan; A.N. Carey; Xuemei Peng; John L. Neumeyer; J.P. McLaughlin
Previous studies have demonstrated that kappa opioid receptor (KOR) antagonists reduce stress- and depression-like behaviors. We hypothesized that administration of a novel opioid mixed agonist/antagonist capable of antagonist activity at the KOR would attenuate forced-swim stress (FSS)-induced immobility, an animal model of depression-like behavior. C57Bl/6J mice were exposed to antinociceptive and repeated FSS testing after pretreatment with a graded dose of a novel bivalent morphinan compound, bis(N-cyclobutylmethylmorphinan-3-yl) sebacoylate dihydrochloride (MCL-144B). MCL-144B demonstrated dose- and time-dependent antinociception and KOR-mediated antagonism. In support of the hypothesis, pretreatment with MCL-144B dose-dependently attenuated stress-induced antinociception and immobility in the forced-swim test.
European Journal of Medicinal Chemistry | 2011
Gianfranco Balboni; Severo Salvadori; Ewa D. Marczak; Brian I. Knapp; Jean M. Bidlack; Lawrence H. Lazarus; Xuemei Peng; Yu Gui Si; John L. Neumeyer
Bifunctional ligands containing an ester linkage between morphine and the δ-selective pharmacophore Dmt-Tic were synthesized, and their binding affinity and functional bioactivity at the μ, δ and κ opioid receptors determined. Bifunctional ligands containing or not a spacer of β-alanine between the two pharmacophores lose the μ agonism deriving from morphine becoming partial μ agonists 4 or μ antagonists 5. Partial κ agonism is evidenced only for compound 4. Finally, both compounds showed potent δ antagonism.
Bioorganic & Medicinal Chemistry Letters | 2007
Xuemei Peng; Brian I. Knapp; Jean M. Bidlack; John L. Neumeyer
A series of carbamate analogues were synthesized from levorphanol (1a), cyclorphan (2a) or butorphan (3a) and evaluated in vitro for their binding affinity at mu, delta, and kappa opioid receptors. Functional activities of these compounds were measured in the [(35)S]GTPgammaS binding assay. Phenyl carbamate derivatives 2d and 3d showed the highest binding affinity for kappa receptor (K(i)=0.046 and 0.051 nM) and for mu receptor (K(i)=0.11 and 0.12 nM). Compound 1c showed the highest mu selectivity. The preliminary assay for agonist and antagonist properties of these ligands in stimulating [(35)S]GTPgammaS binding mediated by the kappa opioid receptor illustrated that all of these ligands were kappa agonists. At the mu receptor, compounds 1b, 1c, 2b, and 3b were agonists, while compounds 2c-e and 3c-e were mu agonists/antagonists.
Journal of Medicinal Chemistry | 2006
Xuemei Peng; Brian I. Knapp; Jean M. Bidlack; John L. Neumeyer
Journal of Medicinal Chemistry | 2007
Xuemei Peng; Brian I. Knapp; Jean M. Bidlack; John L. Neumeyer
ACS Chemical Neuroscience | 2010
Gianfranco Balboni; Severo Salvadori; Claudio Trapella; Brian I. Knapp; Jean M. Bidlack; Lawrence H. Lazarus; Xuemei Peng; John L. Neumeyer
Journal of Medicinal Chemistry | 2006
John L. Neumeyer; Xuemei Peng; Brian I. Knapp; Jean M. Bidlack; Lawrence H. Lazarus; Severo Salvadori; Claudio Trapella; Gianfranco Balboni
Journal of Pharmacology and Experimental Therapeutics | 2005
Jennifer L. Mathews; Xuemei Peng; Wennan Xiong; Ao Zhang; S. Stevens Negus; John L. Neumeyer; Jean M. Bidlack
Current Topics in Medicinal Chemistry | 2007
Xuemei Peng; John L. Neumeyer
Bioorganic & Medicinal Chemistry Letters | 2007
Xuemei Peng; Brian I. Knapp; Jean M. Bidlack; John L. Neumeyer